Literature DB >> 8391095

Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria.

S A Brown1, C L Walton, P Crawford, G L Bakris.   

Abstract

The long-term effects of different antihypertensive regimens were studied in uninephrectomized beagles with alloxan-induced diabetes mellitus. Mean arterial pressure (MAP) was elevated (P < 0.05) in untreated diabetic dogs. Treatment of diabetic dogs with an angiotensin converting enzyme inhibitor (ACEI; lisinopril), a calcium antagonist (CA;TA-3090), or both lowered MAP. At one year, the RBF, GFR, and SNGFR were similarly elevated (P < 0.05) in all groups of diabetic dogs. The increase in SNGFR present in untreated diabetic dogs was primarily attributable to an increased (P < 0.05) glomerular capillary pressure (PGC). Treatment with lisinopril lowered the PGC to a mean value that was indistinguishable from that for nondiabetic dogs. In contrast, diabetic dogs treated with TA-3090 had an elevated PGC. While untreated diabetic dogs exhibited marked increases in glomerular volume (P < 0.05 vs. nondiabetic dogs), treatment with lisinopril and TA-3090, either alone or in combination, blunted the extent of glomerular hypertrophy observed in diabetic dogs (P < 0.05 vs. untreated diabetic dogs). Proteinuria was similarly reduced (P < 0.05 vs. untreated diabetic dogs) in dogs treated with lisinopril and TA-3090. Combination therapy of diabetic dogs produced a further significant (P < 0.05) decrement in proteinuria. We conclude that although treatment of diabetic dogs with either lisinopril or TA-3090 results in differential effects on PGC; each produces a similar decrement in proteinuria. Further, combination therapy has a greater effect on proteinuria than either agent alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8391095     DOI: 10.1038/ki.1993.171

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Cost containment for treating hypertension in African Americans: impact of a combined ACE inhibitor-calcium channel blocker.

Authors:  D S Kountz
Journal:  J Natl Med Assoc       Date:  1997-07       Impact factor: 1.798

Review 2.  Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.

Authors:  Jay Garg; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 3.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

4.  Canine and equine mesangial cells in vitro.

Authors:  D Ennulat; S A Brown
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-09       Impact factor: 2.416

Review 5.  The diabetic patient with hypertension.

Authors:  G P Leese; M W Savage; P D Chattington; J P Vora
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

Review 6.  Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life.

Authors:  M E Cooper; D Vranes; J R Rumble
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

7.  Chronic sodium-retaining action of insulin in diabetic dogs.

Authors:  M Marlina Manhiani; Michael T Cormican; Michael W Brands
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

8.  The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.

Authors:  A A Taylor; S Sunthornyothin
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 9.  Salt, hypertension and renal disease: comparative medicine, models and real diseases.

Authors:  A R Michell
Journal:  Postgrad Med J       Date:  1994-10       Impact factor: 2.401

10.  Amlodipine Reduces Inflammation despite Promoting Albuminuria in the Streptozotocin-Induced Diabetic Rat.

Authors:  Elizabeth R Flynn; David C Marbury; R Taylor Sawyer; Jonathan Lee; Christine Teutsch; Katalin Kauser; Christine Maric-Bilkan
Journal:  Nephron Extra       Date:  2012-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.